Abstract
A solid phase extraction based 177mLu-177Lu separation method has been investigated for its feasibility to be used in the radionuclide generator. The use of 2,2′,2”-(10-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid, (DOTAGA-anhydride) allowed grafting of DOTA (1,4,7,10-tetraazacyclododecane N,N′,N″,N‴-tetraacetic acid) complex on the surface of commercially available amino propyl silica. The grafting of DOTA has been confirmed by several characterization techniques. The thermogravimetric analysis reveals that the 0.33 mmol DOTA groups have been grafted per gram of silica. However, during the Lu ion complexation, a 10 times lower Lu adsorption capacity of 0.03 mmol g−1 could be achieved under the studied reaction conditions. The results indicate that the grafting of DOTA on solid affects the Lu coordination and also influences the kinetics of Lu-DOTA complexation. The weak coordination resulted in high 177mLu leakage, while the unreacted DOTA groups interfer with the 177Lu release. This is evident from the 0.3% 177mLu leakage combined with a177Lu extraction efficiency of 25%. Overall, the results show a177mLu-177Lu separation with a maximum 177Lu/177mLu activity ratio of 25. But this is still far away from clinically acceptable activity ratio of 10,000 for which future work is recommended.
Highlights
Lutetium-177 (177Lu) is a radionuclide with tremendous potential in the field of nuclear medicine (Banerjee et al, 2015). [177Lu]Lu-DOTA TATE has been approved for neuroendocrine tumor treatment and clinical studies involving the application of other 177Lu based radio pharmaceuticals in the treatment of prostate cancer, bone pain pallia tion among others are in progress (Banerjee et al, 2015)
The surface morphology of the starting amino propyl silica and the synthesized DOTA grafted silica particles were examined by Scanning electron microscopy (SEM) anal ysis (Fig. 2)
The presented work is the first step in designing a solid phase extraction based 177mLu-177Lu separation
Summary
Lutetium-177 (177Lu) is a radionuclide with tremendous potential in the field of nuclear medicine (Banerjee et al, 2015). [177Lu]Lu-DOTA TATE has been approved for neuroendocrine tumor treatment and clinical studies involving the application of other 177Lu based radio pharmaceuticals in the treatment of prostate cancer, bone pain pallia tion among others are in progress (Banerjee et al, 2015). The SPE based 177mLu-177Lu separation requires a solid support that should i) be chemically stable ii) allow 177mLu complexa tion and iii) permit the elution of free 177Lu ions while retaining the complexed 177mLu ions. The application of majority of these solids lies in metal ion recovery (Kocyigit et al, 2012; Gangoda et al, 2016; Hirose et al, 2003; Wu et al, 2016; Zhai et al, 2016; Erdem et al, 2011) or use as silica supported metal catalysts (Tamami et al, 2013) and has never been used for any radionuclide generator development. 177mLu cations have been adsorbed on the solid surface and tested under different elution conditions that can allow the removal of 177Lu ions while keeping the leakage of complexed 177mLu ions minimal
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
